We are building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases
- Discovery
- Pre-clinical
- Phase I
- Phase II
2020 Milestone
Small molecule targeting S1P1 (Th1 cell modulator)
Ulcerative Colitis
Chron's Disease
- Report topline Ph2a CD data in Q3
Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)
Atopic Dermatitis
Asthma
Nasal Polyps
- Report topline Ph1b AD data in Q1
- Initiate Ph2 AD trial in Q2
Small molecule (target undisclosed)
Pruritis
- Initiate Ph1 study in Q2
- Report Ph1 topline data in Q4